Targeted Therapy in Early-Stage HER2+ Breast Cancer
Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.
Related Articles
Cell Therapies Emerge for the Treatment of Acute Myeloid Leukemia
Cellular therapies are an effective option in hematologic malignancies but have been slower to develop in AML, but identifying new targets paves the way for…
Updates on the iNTEGRATE and ROCKstar Trials
Yi-Bin Chen, MD, provides an overview of the iNTEGRATE and ROCKstar trials, underscoring their significance in the current treatment paradigm for graft versus host disease,…
Real-World Study Evaluates Racial and Socioeconomic Disparities in CLL
Ira Zackon, MD, discusses the background of a real-world study which sought to identify some of the racial and socioeconomic disparities seen in patients with…
Exploring the Link Between HPV Infection and Head and Neck Cancers
In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link between human papillomavirus infection and…
Lessons Learned from REACH-3 Clinical Trial
Yi-Bin Chen, MD, presents the results of the phase-3 randomized REACH-3 Trial, highlighting the superior best overall response rate of 75% in the experimental arm…
Lenvatinib Is Effective, Regardless of Age in HCC
No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.
Behind the CheckMate-77T Trial of a Nivolumab-Based Regimen in NSCLC
Tina Cascone, MD, PhD, discusses the CheckMate-77T trial of perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab for the treatment…
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients…
Legislative Changes and Their Impact on Community Oncology Care
In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.
GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma
At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.